Bayer and Regenron Agreed to Jointly Develop Treatment for Eye Disease
Bayer AG's Bayer Healthcare unit and Regeneron Pharmaceuticals Inc. agreed to jointly develop, and commercialize a treatment for eye disease.
The treatment, knows as VEGF Trap-Eye, blocks vascular endothelial growth factor, a protein that is responsible for blood vessel growth. By blocking VEGF, blood vessels that contribute to eye disease are starved of much needed oxygen and nutrients.
The agreement covers the world outside the United States, the companies said in a statement. Within the U.S., Regeneron has exclusive commercial rights and will retain 100 percent of all profits.
Filed under Eye Treatment
You may also like to read
- Couple Forced to Choose Which One of Them Should Go Blind
- Sirion Therapeutics is Ready to Develop New Treatment for Viral and Superficial Eye Infection
- Melanoma, A Rare Form Of Cancer Can Be Treated With Laser Therapy
- Syphilis Related Eye Infections are Rising Fast
- Brand New Treatment For Macular Degeneration
- Asthma Drugs May Increase Cataract Risks in Elderly
- Indian President Dr. A P J Abdul Kalam Declares “defect-free vision for all” as National Mission; Promotes Stem Cell Research and Nano Technology
- Cholesterol-Lowering drug May be Good for Avoiding Cataract
- Sickle Cell Disease Can Cause Sudden Painless Vision Loss
- Type 2 Diabetes May Lead To Glaucoma Risk
